300705.SHE Hunan Jiudian Pharmaceutical Co Ltd
- Market cap
- CNY 5.16B
- P/E
- 16.4x
- P/B
- 1.89x
- ROE
- 12.0%
- Dividend yield
- 3.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300705.SHE undervalued?
Graham number300705.SHE trades 17.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Jiudian Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hunan Jiudian Pharmaceutical Co Ltd yet.
Hunan Jiudian Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches, ketoprofen gel patches, pantopril sodium enteric-coated tablets, dapagliflozin …
Full company profileHunan Jiudian Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Jiudian Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 376M | 535M | 801M | 924M | 978M | 1.63B | 2.33B | 2.69B | 2.93B | 3.11B | 2.73B |
| Gross Profit | 194M | 277M | 477M | 622M | 725M | 1.26B | 1.80B | 2.07B | 2.14B | 2.27B | 1.69B |
| Operating Income | 60.8M | 74.8M | 80.2M | 62.9M | 91.7M | 226M | 291M | 394M | 575M | 583M | 425M |
| EBITDA | 74.9M | 87.4M | 96.0M | 90.2M | 126M | 265M | 338M | 446M | 634M | 666M | 405M |
| Net Income | 54.5M | 68.6M | 72.0M | 55.1M | 82.3M | 204M | 270M | 368M | 512M | 473M | 320M |
| EPS | 0.23 | 0.26 | 0.22 | 0.17 | 0.25 | 0.62 | 0.69 | 1.07 | 1.04 | 0.95 | 0.64 |
| Balance Sheet | |||||||||||
| Total Assets | 397M | 769M | 943M | 1.07B | 1.13B | 1.75B | 2.30B | 2.87B | 3.37B | 4.02B | 4.40B |
| Total Liabilities | 73.6M | 109M | 225M | 310M | 295M | 646M | 747M | 898M | 846M | 1.23B | 1.57B |
| Shareholders' Equity | 323M | 660M | 718M | 762M | 836M | 1.10B | 1.55B | 1.97B | 2.53B | 2.66B | 2.68B |
| Cash & Short-term Investments | 70.8M | 298M | 171M | 132M | 135M | 499M | 436M | 515M | 704M | 454M | 575M |
| Total Debt | 20.0M | 4.00M | 79.7M | 140M | 88.4M | 329M | 316M | 384M | 294M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.2M | 80.4M | 68.2M | 90.7M | 150M | 191M | 269M | 431M | 746M | 647M | - |
| Capital Expenditure | 31.4M | 97.8M | 257M | 182M | 78.4M | 126M | 413M | 427M | 398M | 653M | 304M |
| Free Cash Flow | 23.8M | -17.3M | -189M | -91.2M | 71.6M | 64.9M | -144M | 4.37M | 348M | -5.83M | 336M |
| Ratios | |||||||||||
| ROE | 16.9% | 10.4% | 10.0% | 7.2% | 9.8% | 18.6% | 17.4% | 18.7% | 20.3% | 17.8% | 12.0% |
| ROA | 13.7% | 8.9% | 7.6% | 5.1% | 7.3% | 11.7% | 11.7% | 12.8% | 15.2% | 11.8% | 7.3% |
| Net Profit Margin | 14.5% | 12.8% | 9.0% | 6.0% | 8.4% | 12.5% | 11.6% | 13.7% | 17.5% | 15.2% | 11.7% |
| Debt to Equity | 0.06x | 0.01x | 0.11x | 0.18x | 0.11x | 0.30x | 0.20x | 0.19x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Jiudian Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.12%
- Forward dividend
- 0.40 CNY
- Payout ratio
- 34.0%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 161M | 0.32 | 34.0% |
| 2024 | CNY 116M | 0.23 | 22.6% |
| 2023 | CNY 94.6M | 0.27 | 25.7% |
| 2022 | CNY 61.3M | 0.16 | 22.7% |
| 2021 | CNY 10.1M | 0.03 | 4.9% |
| 2020 | CNY 8.45M | 0.03 | 10.3% |
| 2019 | CNY 11.0M | 0.03 | 20.0% |
| 2018 | CNY 15.5M | 0.05 | 21.6% |
| 2017 | CNY 677K | 0.00 | 1.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 24, 2024.
Who owns Hunan Jiudian Pharmaceutical Co Ltd
- Insiders 49.09%
- Institutions 0.60%
- Public & others 50.31%
- Shares outstanding 500M
- Free float 353M
Hunan Jiudian Pharmaceutical Co Ltd company profile
- Company name
- Hunan Jiudian Pharmaceutical Co Ltd
- Ticker
- 300705.SHE
- ISIN
- CNE1000034Z6
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,298
- Fiscal year end
- December
- Address
- Building A1, Wukuang Lugu Science and Technology Industry Park, Changsha, China, 410205
- Phone
- 86 731 8822 0222
- Website
- hnjiudian.com
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches, ketoprofen gel patches, pantopril sodium enteric-coated tablets, dapagliflozin tablets, and rosuvastatin calcium. It also provides digestive system and metabolic, nervous system, cardiovascular system medications, musculoskeletal, anti-infective, respiratory system medications, blood and hematopoietic system, and reproductive and urinary system and hormone drugs. In addition, the company offers CMO/CDMO; software development and technical; and pharmaceutical retail services. Hunan Jiudian Pharmaceutical Co., Ltd. was founded in 2001 and is based in Changsha, China.
Hunan Jiudian Pharmaceutical Co Ltd management
5- Ms. Ying XiongFinancial Director · born 1964
- Mr. Pengyun FanDeputy GM & Director · born 1977
- Ms. Lei ZengDeputy GM & Secretary of the Board · born 1985
- Mr. Yang YangNon-Independent Director & GM · born 1984
- Guo WangAccounting Supervisor